

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner of Patents and Trademarks, Washington, D.C. 20231, on

Date: May 25, 1999 Atty's Reg. # 19,805

JOHN Q. McQUILLAN

References to ADEPT

- EXH. A**
- C. W. Parker et al., "Enzymatic Activation and Trapping of Luminol-Substituted Peptides and Proteins. A Possible Means of Amplifying the Cytotoxicity of Anti-Tumor Antibodies", Proc. Natl. Acad. Sci. U.S.A., 72, (No. 1), 338-342, (1975).
 - G. W. Philpott et al., "Selective Iodination and Cytotoxicity of Tumor Cells with an Antibody-Enzyme Conjugate", Surgery, 74, pp. 51-58, (1973), (Philpott I).
 - G. W. Philpott et al., "Selective Cytotoxicity of Hapten-Substituted Cells with an Antibody-Enzyme Conjugate", J. Immunol., 111, (No. 3), pp. 921-929, (1973), (Philpott II).
 - M. J. Robins et al., "Nucleic Acid Related Compounds. 16. Direct Fluorination of Uracil Nucleotides Using Trifluoromethyl Hypofluorite", Can. J. Chem., 53, pp. 1302-1306, (1975).
 - G. F. Rowland et al., "Drug Localization and Growth Inhibition Studies of Vindesine-Monoclonal Anti-CEA Conjugates in a Human Tumour Xenograft", Cancer Immunol. Immunother., 21, pp. 183-187, (1986).
 - F. Searle et al., "Antibody Carboxypeptidase G₂ Conjugates as Anti-Tumor Agent", Tumor Biology, 6, (No. 4), p. 355, (1985), (Searle I).
 - F. Searle et al., "Carboxypeptidase G₂ Conjugates with Localizing Anti-Tumour Antibodies: Potential Therapeutic Agents", Tumor Biology, 7, (No. 4), p. 320, (1986), (Searle II).
 - F. Searle et al., "The Potential of Carboxypeptides G₂ -Antibody Conjugates as Anti-Tumour Agents. I. Preparation of Antihuman Chorionic Gonadotrophin-Carboxypeptidase G₂ and Cytotoxicity of the Conjugate Against JAR Choriocarcinoma Cells In Vitro", Br. J. Cancer, 53, pp. 377-384, (1986), (Searle III).
 - W. T. Shearer et al., "Cytotoxicity with Antibody-Glucose Oxidase Conjugates Specific for a Human Colonic Cancer and Carcinoembryonic Antigen", Int. J. Cancer, 14, pp. 539-547, (1974).
 - V. J. Stella et al., "Prodrugs: Do They Have Advantages in Clinical Practice?", Drugs, 29, pp. 455-473, (1985), (Stella I).
 - W. A. Thomas, "Prodrugs", Biochemical Society Transactions, 14, pp. 383-387, (615th Meeting, Belfast, 1986).
 - P. E. Thorpe et al., "The Preparation and Cytotoxic Properties of Antibody-Toxin Conjugates", Immunological Rev., 62, pp. 119-158, (1982), (Thorpe I).
 - P. E. Thorpe, "Antibody Carriers of Cytotoxic Agents in Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological and Clinical Applications, A. Pinchera et al., (eds.), pp. 475-506, (1985), (Thorpe II).
 - E. S. Vitetta et al., "Redesigning Nature's Poisons to Create Anti-Tumor Reagents", Science, 238, pp. 1098-1104, (1987).
 - M. Y. Yeh et al., "Cell Surface Antigens of Human Melanoma Identified by Monoclonal Antibody", Proc. Natl. Acad. Sci., 76, (No. 6), pp. 2927-2931, (1979), (Yeh I).
 - M. Y. Yeh et al., "Clonal Variation in Expression of a Human Melanoma Antigen Defined by a Monoclonal Antibody", J. Immunol., 126, (No. 4), pp. 1312-1317, (1981), (Yeh II).
 - Hellstrom et al., Cancer Research, 46, (Aug. 1986), 3917-3923.
 - Philpott et al., Cancer Research, 34, (1974), 2159-2164.
 - Hellstrom et al., J. Immunol., 127(1), (1981), 157-160.
 - Stella et al., in Directed Drug Delivery, (1985), pp. 247-267.
 - Nishiyama et al., Cancer Research, 45, (1985), 1753-1761.
 - Wilman, Biochem. Soc. Trans., 14, (615th Meeting, Belfast, 1986), 375-382.
 - O'Dwyer et al., N. Eng. J. Med., 312, (1985), 692-700.
 - A. P. Albino et al., "Heterogeneity in Surface Antigen and Glycoprotein Expression of Cell Lines Derived from Different Melanoma Metastases of the Same Patient", J. Exp. Med., 154, pp. 1764-1778, (1981).
 - R. Arnon et al., "In Vitro and In Vivo Efficacy of Conjugates of Daunomycin with Anti-Tumor

References to ADEPT

- Antibodies", *Immunological Rev.*, 62, pp. 5-27, (1982).
- K. D. Bagshawe, "Antibody Directed Enzymes Revive Anti-Cancer Prodrugs Concept", *Br. J. Cancer*, 56, (No. 5), pp. 531-532, (Nov. 1987), (Bagshawe I).
- K. D. Bagshawe et al., "A Novel Approach to Prodrug Activation Using a Monoclonal Antibody Conjugated to Carboxypeptidase G₂", from the Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer, Abstract #43, p. 70, (San Diego, Feb. 4-6, 1988) (Bagshawe II).
- R. W. Baldwin et al., "Design and Therapeutic Evaluation of Monoclonal Antibody 791T/36-Methotrexate Conjugates", in *Monoclonal Antibodies and Cancer Therapy*, pp. 215-231, (Alan R. Liss, Inc., 1985), (Baldwin I).
 - R. W. Baldwin et al., "Monoclonal Antibodies in Cancer Treatment", *Lancet*, pp. 603-605, (Mar. 15, 1986), (Baldwin II).
 - R. W. Baldwin et al., "Monoclonal Antibody Drug Conjugates for Cancer Therapy", in *Monoclonal Antibodies in Cancer: Advances in Diagnosis and Treatment*, Jack A. Roth (ed.), pp. 215-257, (Futura Publishing Co., 1986), (Baldwin III).
 - J. P. Brown et al., "Structural Characterization of Human Melanoma-Associated Antigen p97 with Monoclonal Antibodies", *J. Immunol.*, 127, (No. 2), pp. 539-546, (1981).
 - E. A. Clark et al., "Role of the Bp35 Cell Surface Polypeptide in Human B-Cell Activation", *Proc. Natl. Acad. Sci.*, 82, pp. 1766-1770, (1985).
 - S. T. Crooke et al. (eds.), *Antiracyclines: Current Status and New Developments*, Academic Press, (New York, 1980).
 - R. A. DeWeger et al., "Eradication of Murine Lymphoma and Melanoma Cells by Chlorambucil-Antibody Complexes", *Immunological Rev.*, 62, pp. 29-45, (1982).
 - M. J. Embleton et al., "Antibody Targeting of Anti-Cancer Agents", in *Monoclonal Antibodies for Cancer Detection and Therapy*, R. W. Baldwin and V. S. Byers (eds.), pp. 321-322, (Academic Press, 1985), (Embleton I).
 - M. J. Embleton, "Targeting of Anti-Cancer Therapeutic Agents by Monoclonal Antibodies", *Biochemical Society Transactions*, 14, pp. 393-395, (615th Meeting, Belfast, 1986), (Embleton II).
 - N. Endo et al., "In Vitro Cytotoxicity of a Human Serum Albumin-Mediated Conjugate of Methotrexate with Anti-MM46 Monoclonal Antibody", *Cancer Research*, 47, pp. 1076-1080, (Feb. 1987).
 - P. J. Fraker et al., "Protein and Cell Membrane Iodinations with a Sparingly Soluble Chloroamide, 1,3,4,6-Tetrachloro-3a,6a-Diphenylglycoluril", *Biochem. Biophys. Res. Commun.*, 80, (No. 4), pp. 849-857, (1978).
 - I. Hellstrom et al., "Antitumor Effect of L6, an IgG₂ a Antibody that Reacts with Most Human Carcinomas", *Proc. Natl. Acad. Sci. U.S.A.*, 83, pp. 7059-7063, (1986).
 - I. Hellstrom et al., "Antibodies for Drug Delivery", in *Controlled Drug Delivery*, (2nd ed.), Robinson and Lee (eds.), p. 639, (1987), (Hellstrom IV).
 - P. L. Ipata et al., "Baker's Yeast Cytosine Deaminase. Some Enzymatic Properties and Allosteric Inhibition by Nucleosides and Nucleotides", *Biochemistry*, 10, pp. 4270-4276, (1971).
 - T. Katsuragi et al., "Affinity Chromatography of Cytosine Deaminase from *Escherichia coli* with Immobilized Pyrimidine Compounds", *Agric. Biol. Chem.*, 50, (No. 7), pp. 1713-1719, (1986).
 - J. M. Lambert et al., "Purified Immunotoxins That Are Reactive with Human Lymphoid Cells", *J. Biol. Chem.*, 260, (No. 22), pp. 12035-12041, (1985).
 - J. P. Mach et al., "Improvement of Colon Carcinoma Imaging: from Polyclonal Anti-CEA Antibodies and Static Photoscanning to Monoclonal Fab Fragments and ECT", in *Monoclonal Antibodies for Cancer Detection and Therapy*, R. W. Baldwin et al. (eds.), pp. 53-64, (Academic Press, 1985).
 - R. B. McComb et al. (eds.), *Alkaline Phosphatase*, Plenum Press, (New York, 1979).
 - R. G. Melton et al., "In Vivo Localization of Carboxypeptidase G₂ : Antibody Conjugates in Human Colon Carcinoma Xenografts", from the Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer, Abstract #83, p. 110, (San Diego, Feb. 4-6, 1988).
 - S. Monfardini et al. (eds.), *Manual of Cancer Chemotherapy*, (3rd ed.), UICC Technical Report